Literature DB >> 1357957

Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function?

J H Krystal1, L H Price, C Opsahl, G A Ricaurte, G R Heninger.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a selective serotonin (5-HT) neurotoxin in animals. There is now preliminary evidence in humans of 5-HT deficits associated with extensive use of MDMA. In order to begin to describe the cognitive and mood effects of chronic MDMA use, nine individuals with extensive MDMA use histories were studied. Despite the absence of memory deficits on clinical examination, a pattern of mild-to-moderate impairment was observed on both the Initial and Delayed Paragraph Tests of the Wechsler Memory Scale; eight of the subjects had at least mild impairment on at least one test in the neuropsychological battery. Despite previously reported suggestive evidence of 5-HT deficit in this group, none reported depressed mood or met clinical criteria for an affective disorder at the time of testing. These preliminary findings raise concern about possible detrimental effects of MDMA use on neuropsychological function for future systematic study and they highlight important issues regarding the effects of 5-HT deficits on cognitive function and mood regulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357957     DOI: 10.3109/00952999209026070

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  21 in total

1.  Risky car following in abstinent users of MDMA.

Authors:  Elizabeth Dastrup; Monica N Lees; Antoine Bechara; Jeffrey D Dawson; Matthew Rizzo
Journal:  Accid Anal Prev       Date:  2010-05

2.  5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats.

Authors:  J H Kehne; R A Padich; T C McCloskey; V L Taylor; C J Schmidt
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Chronic cognitive impairment in users of 'ecstasy' and cannabis.

Authors:  Anthony Klugman; John Gruzelier
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

4.  Impaired perception of self-motion (heading) in abstinent ecstasy and marijuana users.

Authors:  M Rizzo; C T J Lamers; C G Sauer; J G Ramaekers; A Bechara; G J Andersen
Journal:  Psychopharmacology (Berl)       Date:  2005-02-19       Impact factor: 4.530

5.  Chronic MDMA (ecstasy) use, cognition and mood.

Authors:  K McCardle; S Luebbers; J D Carter; R J Croft; C Stough
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

6.  Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.

Authors:  Onica Legendre; Stevan Pecic; Sandeep Chaudhary; Sarah M Zimmerman; William E Fantegrossi; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2009-11-20       Impact factor: 2.823

7.  Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users.

Authors:  Karen L Hanson; Monica Luciana; Kristin Sullwold
Journal:  Drug Alcohol Depend       Date:  2008-04-01       Impact factor: 4.492

8.  Tri-city study of Ecstasy use problems: a latent class analysis.

Authors:  Lawrence M Scheier; Arbi Ben Abdallah; James A Inciardi; Jan Copeland; Linda B Cottler
Journal:  Drug Alcohol Depend       Date:  2008-07-31       Impact factor: 4.492

9.  The emerging modern face of mood disorders: a didactic editorial with a detailed presentation of data and definitions.

Authors:  Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2010-04-12       Impact factor: 3.455

10.  Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.

Authors:  G A Ricaurte; U D McCann
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.